REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Replimune Group, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$11.05+0.19 (+1.75%)
Close on Oct 19, 2026
- Market cap
- $1.07B
- P/E (TTM)
- –
- Dividend yield
- –
Replimune Group, Inc. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Replimune's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.